Human mesenchymal stromal cells inhibit platelet activation and aggregation involving CD73-converted adenosine
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Mesenchymal stromal cells (MSCs) are promising cell therapy candidates. Clinical application is considered safe. However, minor side effects have included thromboembolism and instant blood-mediated inflammatory reactions suggesting an effect of MSC infusion on hemostasis. Previous studies focusing on plasmatic coagulation as a secondary hemostasis step detected both procoagulatory and anticoagulatory activities of MSCs. We now focus on primary hemostasis and analyzed whether MSCs can promote or inhibit platelet activation. METHODS: Effects of MSCs and MSC supernatant on platelet activation and function were studied using flow cytometry and further platelet function analyses. MSCs from bone marrow (BM), lipoaspirate (LA) and cord blood (CB) were compared to human umbilical vein endothelial cells or HeLa tumor cells as inhibitory or activating cells, respectively. RESULTS: BM-MSCs and LA-MSCs inhibited activation and aggregation of stimulated platelets independent of the agonist used. This inhibitory effect was confirmed in diagnostic point-of-care platelet function analyses in platelet-rich plasma and whole blood. Using inhibitors of the CD39-CD73-adenosine axis, we showed that adenosine produced by CD73 ectonucleotidase activity was largely responsible for the LA-MSC and BM-MSC platelet inhibitory action. With CB-MSCs, batch-dependent responses were obvious, with some batches exerting inhibition and others lacking this effect. CONCLUSIONS: Studies focusing on plasmatic coagulation suggested both procoagulatory and anticoagulatory activities of MSCs. We now show that MSCs can, dependent on their tissue origin, inhibit platelet activation involving adenosine converted from adenosine monophosphate by CD73 ectonucleotidase activity. These data may have strong implications for safety and risk/benefit assessment regarding MSCs from different tissue sources and may help to explain the tissue protective mode of action of MSCs. The adenosinergic pathway emerges as a key mechanism by which MSCs exert hemostatic and immunomodulatory functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, R. H., Pulin, A. A., Seo, M. J., Kota, D. J., Ylostalo, J., Larson, B. L., Semprun-Prieto, L., Delafontaine, P., & Prockop, D. J. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.05.003 · Cited by 1,898
Karagianni, M., Brinkmann, I., Kinzebach, S., Grassl, M., Weiss, C., Bugert, P., & Bieback, K. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2012.11.001 · Cited by 43 · cited 3×
“Real-time quantitative PCR (RT-qPCR) of procoagulant and anticoagulant factors was performed as described previously [34].”
BackgroundMethodSelf-citation
Cited by
Moll, G., Ankrum, J. A., Kamhieh-Milz, J., Bieback, K., Ringdén, O., Volk, H.-D., Geissler, S., & Reinke, P. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.12.006 · Cited by 440
“…such as heparin in the clinical setting, if applicable, and the reporting of anti-coagulant use within clinical trial protocols (Table S2) [20,89,90] In conclusion, multiple reports have indicated a favorable outcome for minimally expanded fresh cells prepared with non-immunogenic supplements,…”
Self-citationMesenchymal stem cell immunomodulation: in pursuit of controlling COVID-19 related cytokine storm
Song, N., Wakimoto, H., Rossignoli, F., Bhere, D., Ciccocioppo, R., Chen, K.-S., Khalsa, J. K., Mastrolia, I., Samarelli, A. V., Dominici, M., et al. (2021) · Stem Cells · doi:10.1002/stem.3354 · Cited by 62
Torres Crigna, A., Uhlig, S., Elvers-Hornung, S., Klüter, H., & Bieback, K. (2020) · Cells · doi:10.3390/cells9112419 · Cited by 46
Self-citation
Metadata
- Authors
- Netsch, P., Elvers-Hornung, S., Uhlig, S., Klüter, H., Huck, V., Kirschhöfer, F., Brenner-Weiß, G., Janetzko, K., Solz, H., Wuchter, P., Bugert, P., & Bieback, K.
- Venue
- Stem Cell Research & Therapy
- Published
- 2018-07-04
- Volume
- 9
- Issue
- 1
- Pages
- 184-184
- ISSN
- 1757-6512 (ISSN-L)
- OpenAlex
- W2809749672
- Cited by
- 44
- References
- 2
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human mesenchymal stromal cells inhibit platelet activation and aggregation involving CD73-converted adenosine. https://app.cochat.ai/papers/10.1186/s13287-018-0936-8
- The paper
- Netsch, P., Elvers-Hornung, S., Uhlig, S., Klüter, H., Huck, V., Kirschhöfer, F., Brenner-Weiß, G., Janetzko, K., Solz, H., Wuchter, P., Bugert, P., & Bieback, K. (2018). Human mesenchymal stromal cells inhibit platelet activation and aggregation involving CD73-converted adenosine. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-018-0936-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.